Epidemiology of Hepatitis B, C and Delta in Reunion Island

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03362866

Acronym

HEPEPID

Enrollment

2000

Registered

2017-12-05

Start date

2019-01-31

Completion date

2023-04-30

Last updated

2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Hepatitis C, Hepatitis D

Brief summary

Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on Management of people infected with hepatitis B or hepatitis C viruses identifies a residual area of weakness in this care that is the incomplete regional epidemiological data in the Overseas Territories. The specific ethno-socio-cultural characteristics of these territories make it difficult to transpose data from the mainland France. This study aims at improving our knowledge on the characteristics of patients with hepatitis B, C and Δ in Reunion Island, their follow-up, their evolution and complications.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Major patient * with confirmed HBsAg and / or anti HCV positive Ab * residing in Reunion Island * followed in one of the participating centers

Exclusion criteria

• Patient carrying isolated anti HBc antibodies

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with hepatitis B, C and Δ in Reunion	Up to 5 years	Hepatitis diagnosis will be made according to the ongoing guidelines in France (referred by the National AIDS and Hepatitis Research Agency (ANRS)

Contacts

Primary ContactOlivier Maillard, PharmD

olmaillard@yahoo.fr+262693025589

Outcome results